Assenagon Asset Management S.A. Sells 99,178 Shares of NextCure, Inc. (NASDAQ:NXTC)

Assenagon Asset Management S.A. reduced its holdings in shares of NextCure, Inc. (NASDAQ:NXTC) by 53.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 85,308 shares of the company’s stock after selling 99,178 shares during the quarter. Assenagon Asset Management S.A.’s holdings in NextCure were worth $117,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Logos Global Management LP lifted its holdings in NextCure by 29.9% during the 2nd quarter. Logos Global Management LP now owns 2,500,000 shares of the company’s stock valued at $3,975,000 after purchasing an additional 575,000 shares during the last quarter. Affinity Asset Advisors LLC raised its position in shares of NextCure by 24.2% in the second quarter. Affinity Asset Advisors LLC now owns 1,687,955 shares of the company’s stock valued at $2,684,000 after purchasing an additional 328,918 shares during the period. Vanguard Group Inc. raised its position in shares of NextCure by 9.3% in the first quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock valued at $2,202,000 after purchasing an additional 83,700 shares during the period. Renaissance Technologies LLC lifted its stake in shares of NextCure by 15.4% during the 2nd quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock worth $735,000 after buying an additional 61,744 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in shares of NextCure during the 2nd quarter worth about $57,000. 42.65% of the stock is owned by institutional investors and hedge funds.

NextCure Price Performance

NXTC opened at $1.33 on Monday. The business has a fifty day simple moving average of $1.40 and a 200 day simple moving average of $1.50. NextCure, Inc. has a 1 year low of $1.03 and a 1 year high of $2.57. The company has a market capitalization of $37.21 million, a PE ratio of -0.61 and a beta of 0.80.

NextCure (NASDAQ:NXTC) last announced its earnings results on Thursday, August 1st. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.19). Equities analysts anticipate that NextCure, Inc. will post -1.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a “buy” rating and issued a $4.00 price target on shares of NextCure in a report on Friday, August 2nd.

NextCure Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.